Skip to content

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

PUBLICATIONS

Heavily Pre-Treated Breast Cancer Patients show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 in Combination with Paclitaxel

By Graviton / 12/2016

San Antonio Breast Cancer Symposium

FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression

By natalia / 12/2016

EBioMedicine

Pharmacological inhibition of FASN Prevents High Fat Diet Induced Liver Damage in Mice and Significantly Reduces de novo Lipogenesis in Humans

By Graviton / 11/2016

AASLD The Liver Meeting

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase Inhibitor, TVB-2640

By Graviton / 11/2016

NCRI Cancer Conference

Mechanism and rationale for inhibition of FASN as a novel therapy for KRAS-mutant non-small cell lung cancer patients

By natalia / 09/2016

Precison: Lung Cancer R&D Summit

DeNovo Palmitate Synthesis Supports Oncogenic Signaling Through Diverse Mechanisms: Implications for FASN-Targeted Therapeutics

By natalia / 08/2016

Journal of Cell Signaling

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

By Graviton / 06/2016

ASCO Annual Meeting

FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study

By Graviton / 04/2016

AACR Annual Meeting

Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640

By Graviton / 04/2016

AACR Annual Meeting

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

By Graviton / 03/2016

International Congress on Targeted Anticancer Therapies

Post pagination

← Previous 1 … 5 6 7 … 9 Next →

Site map

About
Science
Investors
Programs
Contact

About
Science
Investors
Programs
Contact

Contact us

Business Development
bd@sagimet.com

Investors
ir@sagimet.com

Media
media@sagimet.com

Human Resources
hr@sagimet.com

© 2025 Sagimet Biosciences. All Rights Reserved. Terms of Use Agreement | Privacy Policy | Clinical Trial Privacy Notice

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

Scroll to Top